Pharmacokinetics of the Intralesional administration with two doses of rhEGF (75 microg and 225 microg) in patients with advance Diabetic Foot Ulcers

Trial Profile

Pharmacokinetics of the Intralesional administration with two doses of rhEGF (75 microg and 225 microg) in patients with advance Diabetic Foot Ulcers

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Recombinant epidermal growth factor (Primary)
  • Indications Diabetic foot ulcer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 18 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top